What 'liquid cartilage injection' actually refers to

Searching for 'liquid cartilage injection' returns results for at least three structurally different knee treatments, and the phrase itself appears in none of the clinical guidelines. That gap between popular language and medical classification is the first thing worth resolving.

The oldest entry is hyaluronic acid (HA) viscosupplementation — the gel shot that has been used in knee clinics since 1974 and that patients first nicknamed 'liquid cartilage'. It works by replenishing joint fluid to improve lubrication; it does not rebuild cartilage tissue.

More recently, ChondroFiller® — a CE-marked acellular collagen scaffold from Meidrix Biomedicals GmbH — trademarked 'Liquid Cartilage™' as its own brand name. The mechanism is entirely different: it sets inside the joint and is intended to support the body's own repair processes at a focal cartilage defect, not merely to lubricate.

A third, emerging category covers cellular and biological injectables — platelet-rich plasma (PRP), mesenchymal stem cells (MSCs), and exosomes — which target cartilage pathology through biological pathways and remain largely investigational.

Evidence maturity, patient selection criteria, and realistic outcomes differ substantially across all three. The sections below address each in turn.

How ChondroFiller (Liquid Cartilage™) works as a collagen scaffold

ChondroFiller® is manufactured by Meidrix Biomedicals GmbH and holds CE-marking as a Class III medical device — the highest-risk category under European medical device regulation — reflecting the rigour of its approval pathway. The active material is an acid-extracted Type I collagen supplied as a liquid in a two-chamber syringe.

Delivery in current clinical practice is as an ultrasound-guided outpatient injection, placing the collagen into the joint without incision, general anaesthetic, or an operating theatre. Once inside the neutral-pH environment of the knee, the liquid undergoes rapid self-polymerisation, setting into a dimensionally stable hydrogel within approximately three to five minutes and filling the defect surface.

The mechanism is acellular matrix-induced chondrogenesis. The scaffold does not introduce ready-made cartilage cells; instead, it provides a temporary structural framework that recruits the patient's own progenitor cells from the synovium and subchondral bone as the scaffold gradually resorbs. The repair work is therefore done by the patient's biology, guided by the scaffold — not by the injected material itself.

Patient selection matters here. ChondroFiller is indicated for focal, clearly defined Grade III or IV articular cartilage lesions — areas of substantial thinning or full-thickness loss confined to a specific zone. Patients with diffuse, end-stage osteoarthritis fall outside this indication, which is a meaningfully different phenotype from the broad knee OA population for whom HA is typically considered.

Early outcome data report International Knee Documentation Committee (IKDC) scores improving by approximately 30 points, MOCART cartilage assessment scores in the range of 70–87, and a complaint rate of around 0.06%. These figures come from early clinical experience and CE-marking data rather than from large independent head-to-head randomised controlled trials, which have not yet been published. The mechanistic rationale is genuinely distinct from viscosupplementation, but the long-term evidence base remains in development.

Hyaluronic acid: the most-studied injectable and its limits

Hyaluronic acid has the longest clinical track record of any knee injectable — used since 1974, when Peyron and Balazs first described intra-articular sodium hyaluronate in arthritic joints, and supported by a Cochrane systematic review (Bellamy et al., 2006) as well as decades of subsequent trial data. That volume of evidence makes it the natural benchmark against which newer products are measured.

The mechanism is lubrication, not regeneration. HA replenishes the viscoelastic properties of depleted synovial fluid, reducing friction and providing a degree of anti-inflammatory benefit. It does not repair, rebuild, or replace cartilage tissue — a distinction that matters when patients encounter the phrase 'liquid cartilage' in association with gel injections.

Molecular weight is clinically relevant

Not all HA products perform equally. A Level I Bayesian network meta-analysis (n=9,822) found that ultra-high and high molecular weight (UHMW/HMW) products — such as Hylan G-F 20/Synvisc — produced the greatest reduction in VAS pain scores at six months, while low molecular weight HA fell short of control group performance. Grouping all 'gel injections' together obscures this difference. A 2025 umbrella systematic review confirmed moderate efficacy for pain and physical function in early-to-moderate OA, with hybrid and combination formulations showing incremental benefit.

Who responds less well — and guideline disagreement

A cross-sectional study of 149 knees found mean HA effectiveness lasted approximately 48 weeks, but that figure shortens meaningfully in specific patient groups. Independent predictors of shorter duration include BMI above 27.5 kg/m², multicompartmental OA involvement, more than three previous viscosupplementation courses, and a sedentary lifestyle. Advanced radiological OA stage carries a similarly poor prognosis for response, as confirmed by the 2025 EUROVISCO Delphi consensus.

That same EUROVISCO consensus, drawing on 12 expert panellists across 34 statements, also clarified that age alone is not a barrier; nor are diabetes, moderate-to-severe obesity, gout, meniscocalcinosis, or mild-to-moderate varus or valgus malalignment — common reasons clinicians have historically withheld the treatment.

Guideline bodies are not unified. AAOS and NICE withhold endorsement for routine use; ESCEO and OARSI offer conditional support. This is a factual divide among regulatory and professional bodies, not evidence of a settled consensus in either direction. For patients and referring clinicians, the practical implication is that HA sits on a spectrum: a well-characterised symptomatic intervention with a meaningful response rate in the right patient, but one whose benefits are temporary and whose molecular weight, dosing schedule, and patient phenotype all influence outcome.

Arthrosamid, PRP, and emerging cellular injectables

The remaining injectable categories span a range of mechanisms and evidence maturity — from a licensed hydrogel with randomised trial data to cellular therapies that are still investigational.

Arthrosamid (polyacrylamide hydrogel) is a permanent, non-biodegradable hydrogel licensed for knee OA. A subgroup analysis of 239 participants randomised to Arthrosamid or HA (Synvisc-One) found it non-inferior at 26 weeks and approaching superiority at 52 weeks (p=0.057). Patients aged under 70, with normal BMI, or Kellgren–Lawrence grade 2–3 disease — the radiological scale used to stage OA severity — showed the clearest benefit; grade 4 knees favoured HA. Arthrosamid does not repair cartilage structure and is mechanistically distinct from ChondroFiller, which aims to scaffold endogenous repair rather than act as a permanent filler.

Platelet-rich plasma (PRP) has emerging superiority data over HA at 6–12 months in a 2025 systematic review and meta-analysis. A 2024 double-blind randomised trial also found lower T2 mapping values — an MRI measure of cartilage water content that reflects structural quality — in the PRP group versus corticosteroid at twelve months, a potentially protective signal. Against that, the RESTORE trial (JAMA 2021, n=288, mild-to-moderate OA) found no measurable difference in tibial cartilage volume between PRP and placebo despite some pain benefit — a clear example of symptomatic and structural endpoints diverging. Preparation method further complicates comparison: leukocyte-poor and leukocyte-rich formulations behave differently, making cross-trial conclusions unreliable.

MSC injections and exosomes remain investigational. Small randomised studies — including a phase II adipose-derived MSC trial (40 patients) and a double-blind bone marrow–derived MSC study (24 patients, 2025) — have reported MRI cartilage thickness increases, T2 preservation, and inflammatory marker reduction. A 2026 systematic review of seven RCTs found MSC therapy outperformed HA on pain and function scores across all included studies, though long-term durability data are absent for all these approaches.

None of these injectables — including PRP — should be equated with native cartilage regeneration.

Reading the evidence: what trials actually measure

Two questions sit beneath every trial headline: did the treatment reduce pain, and did it protect or restore cartilage structure? These are not the same question, and the answer to one does not predict the answer to the other.

Trials measure pain and function through patient-reported scores — VAS, KOOS, IKDC. Structural change is measured differently: MRI cartilage volume, T2 mapping (which reflects the water content and fibre organisation of cartilage tissue), and MOCART scores for focal defects. As the PRP data above illustrates, a treatment can relieve symptoms without preserving structure on imaging — the endpoints diverge, and neither alone tells the full story.

Corticosteroid injections add a different dimension: a structural harm signal rather than simply an absence of benefit. A 2023 meta-analysis of six studies (n=1,437) found intra-articular corticosteroid associated with an odds ratio of 2.01 (95% CI 1.18–3.44) for cartilage structure worsening on MRI or radiograph. A short-term role for acute flares and pre-procedure inflammation control remains — the concern applies specifically to repeated courses over time.

Evidence volume is not the same as evidence quality, and the two can point in opposite directions. HA has the largest injectable trial dataset, but that body of evidence is predominantly symptomatic. ChondroFiller's dataset is smaller and earlier-phase, yet it includes structural imaging endpoints such as MOCART scores; independent structural RCTs have not yet been published. Of the injectables reviewed here, only corticosteroids carry an established structural-harm signal; only ChondroFiller's mechanism is specifically designed to target structural repair — though without independent RCT confirmation, that distinction remains mechanistic rather than proven at trial level.

Matching the injection to the knee problem

The most important fork in the decision is which phenotype applies: a focal, clearly defined Grade III or IV lesion in a joint that is otherwise reasonably preserved is a different clinical problem from diffuse, multicompartmental wear — and treating them with the same product is unlikely to serve either patient well. ChondroFiller is indicated for the former; it falls outside its indication for generalised degeneration.

For diffuse or early-to-moderate OA, selection among HA, Arthrosamid, and PRP turns on several further factors: Kellgren–Lawrence staging, body weight, number of prior injection courses, and treatment goal. Patients under 70 with normal BMI and KL grade 2–3 disease showed the strongest benefit from Arthrosamid in randomised data; among HA products, ultra-high and high molecular weight formulations produced the greatest pain reduction at six months in a Level I Bayesian network meta-analysis of 9,822 patients. Neither repairs cartilage.

Reaching a sound decision requires characterising the knee properly before committing to any pathway. MRI with cartilage-specific sequences — including T2 mapping where indicated — can establish defect size, location, and grade. At Lincolnshire Knee, outpatient assessments at Sleaford or Grantham may include onMRI™ AI-driven cartilage analysis to support that characterisation.

The injectable landscape has expanded considerably, but the underlying principle has not: no product performs at its best when matched to the wrong indication.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.

1. [1] A Cross-Sectional Study of Factors Predicting the Duration of the Efficacy of Viscosupplementation in Knee Osteoarthritis. (2024). https://doi.org/10.3390/jcm13071949 https://doi.org/10.3390/jcm13071949
2. [2] Longitudinal MRI-defined Cartilage Loss and Radiographic Joint Space Narrowing Following Intra-Articular Corticosteroid Injection for Knee OA: Systematic Review and Meta-analysis. (2023). https://doi.org/10.1016/j.ostima.2023.100157 https://doi.org/10.1016/j.ostima.2023.100157
3. [3] Morphological and Quantitative Parametric MRI Follow-up of Cartilage Changes Before and After Intra-articular Injection Therapy in Mild to Moderate Knee OA. (2024). https://doi.org/10.1097/RLI.0000000000001067 https://doi.org/10.1097/RLI.0000000000001067
4. [4] Effect of Intra-articular PRP vs Placebo on Pain and Medial Tibial Cartilage Volume in Knee OA: The RESTORE Randomized Clinical Trial (JAMA 2021). (2021). https://doi.org/10.1001/jama.2021.19415 https://doi.org/10.1001/jama.2021.19415
5. [5] Comparison of Different Molecular Weights of Intra-Articular Hyaluronic Acid Injections for Knee Osteoarthritis: A Level I Bayesian Network Meta-Analysis. (2025). https://doi.org/10.3390/biomedicines13010175 https://doi.org/10.3390/biomedicines13010175
6. [6] Cartilage regeneration and inflammation modulation in knee OA following injection of allogeneic adipose-derived mesenchymal stromal cells: phase II triple-blinded RCT. (2023). https://doi.org/10.1186/s13287-023-03359-8 https://doi.org/10.1186/s13287-023-03359-8
7. [7] Intra-Articular Injection of Human Bone Marrow–Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial. (2025). https://doi.org/10.1177/09636897241303275 https://doi.org/10.1177/09636897241303275
8. [8] Intra-Articular Hyaluronic Acid for Knee Osteoarthritis: A Systematic Umbrella Review. (2025). https://doi.org/10.3390/jcm14041272 https://doi.org/10.3390/jcm14041272
9. [9] EUROVISCO Consensus Guidelines for the Use of Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis Based on Patient Characteristics. (2024). https://doi.org/10.1177/19476035241271970 https://doi.org/10.1177/19476035241271970
10. [10] Particulated Juvenile Articular Cartilage Allograft Transplantation for Patellofemoral Defects: Return to Sport Rates and Patient Reported Outcomes. (2024). https://doi.org/10.1016/j.arthro.2024.02.018 https://doi.org/10.1016/j.arthro.2024.02.018
11. [11] Combined Particulated Juvenile Articular Cartilage Allograft Transplantation With Autogenous Bone Graft for Symptomatic Osteochondral Defects in the Tibial Plateau. (2025). https://doi.org/10.1016/j.eats.2025.103689 https://doi.org/10.1016/j.eats.2025.103689